Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

Inclusion Criteria:

• Adult patients (age >16 years).

• Either:

• Presence of a hypodense pancreatic mass highly suspicious of primary pancreatic cancer with or without distant metastasis as assessed by a Pancreatic Multi-Disciplinary Team (MDT).

Or

o Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its variants.

• Patient is willing and able to undergo additional tumour biopsy (from the primary or a metastatic site) aimed at obtaining sufficient tissue for molecular profiling if this is required.

• Patient is deemed suitable to receive chemotherapy and/or radiotherapy, and/or surgery pending stage of disease at presentation.

• Patient is deemed potentially eligible for a currently open PRIMUS study

• Patient has signed informed consent for screening research tumour biopsy (Consent 1).

• Patient has signed informed consent for Precision-Panc Master Protocol molecular profiling (Consent 2).